Company profile RNA

Avidity Biosciences Inc
avidity biosciences is pioneering a new class of precision medicines – antibody-sirna conjugates (asc™) – to deliver nucleic acid therapeutics against genetic drivers of disease. our ascs have drug-like properties similar to antibodies and antibody-drug conjugates. importantly, their unique sirna-based “payloads” permit selective targeting of disease-associated mrnas ...against virtually any target of interest. our leadership includes seasoned scientists and executives with deep expertise in the fields of antibody conjugation, chemistry, formulations, oligonucleotide therapeutics, drug delivery and cancer biology. our employees are high energy, creative people who are passionate about solving hard problems and bringing new drugs to patients. we strive to work with partners to discover best-in-class molecules with the goal of long-term, joint value creation. we have also attracted support from top-tier investors including f-prime capital, ecor1 capital, brace pharma and other sophisticated Show More
Quarter analysis & expected interest

There is not enough data for Avidity Biosciences -stock -company to provide analysis

Correlation between past revenue and Avidity Biosciences -stock -company search interest

There is not enough data for Avidity Biosciences -stock -company to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Avidity Biosciences -stock -company to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Avidity Biosciences login to provide analysis

Correlation between past revenue and Avidity Biosciences login search interest

There is not enough data for Avidity Biosciences login to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Avidity Biosciences login to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Avidity Biosciences therapies to provide analysis

Correlation between past revenue and Avidity Biosciences therapies search interest

There is not enough data for Avidity Biosciences therapies to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Avidity Biosciences therapies to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for AOC 1001 clinical trial to provide analysis

Correlation between past revenue and AOC 1001 clinical trial search interest

There is not enough data for AOC 1001 clinical trial to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for AOC 1001 clinical trial to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for AOC 1044 clinical trial to provide analysis

Correlation between past revenue and AOC 1044 clinical trial search interest

There is not enough data for AOC 1044 clinical trial to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for AOC 1044 clinical trial to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for AOC 1020 clinical trial to provide analysis

Correlation between past revenue and AOC 1020 clinical trial search interest

There is not enough data for AOC 1020 clinical trial to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for AOC 1020 clinical trial to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for antibody oligonucleotide conjugates to provide analysis

Correlation between past revenue and antibody oligonucleotide conjugates search interest

There is not enough data for antibody oligonucleotide conjugates to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for antibody oligonucleotide conjugates to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for oligonucleotide-based therapies to provide analysis

Correlation between past revenue and oligonucleotide-based therapies search interest

There is not enough data for oligonucleotide-based therapies to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for oligonucleotide-based therapies to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Useful links and data for RNA
Earnings date: 2024-02-27 After close
Company name: Avidity Biosciences Inc
Sector: Manufacturing
Company's website
Hypercharts
Yahoo Finance
MarketWatch
StockTwits
SEC Filings
SwaggyStocks
Latest articles

2026-10-22T10:42:49.202129634Z

Analyst Upgrades
Roth Capital Initiates Coverage On Atrium Therapeutics with Buy Rating, Announces Price Target of $15

2026-10-20T17:23:00-04:00

PR Newswire
Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

2026-10-20T08:09:00-04:00

PR Newswire
Yakira Capital Management Calls on Atrium Therapeutics to Launch Strategic Review, Curb Cash Spending and Explain Dilutive Financing

2026-10-08T06:30:00-04:00

PR Newswire
Atrium Therapeutics Announces $50 Million Private Placement

2026-09-21T16:30:00-04:00

PR Newswire
Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

2026-09-02T08:00:00-04:00

PR Newswire
Atrium Therapeutics to Participate in Upcoming Investor Conferences

2026-08-20T18:23:00-04:00

PR Newswire
Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2026-08-14T17:27:12.186565395Z

Analyst Upgrades
HC Wainwright & Co. Reiterates Buy on Atrium Therapeutics, Maintains $25 Price Target

2026-08-13T16:44:00-04:00

PR Newswire
Atrium Therapeutics Reports Second Quarter 2026 Financial Results

2026-08-13T08:00:00-04:00

PR Newswire
Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration

2026-08-06T14:12:18.006877253Z

Analyst Upgrades
This Lyell Immunopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday

2026-08-06T11:12:05.780136891Z

Analyst Upgrades
HC Wainwright & Co. Initiates Coverage On Atrium Therapeutics with Buy Rating, Announces Price Target of $25

2026-07-20T17:58:00-04:00

PR Newswire
Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

2026-07-14T06:30:00-04:00

PR Newswire
Atrium Therapeutics Announces FDA Clearance of Investigational New Drug Application for ATR 1072 for Treatment of PRKAG2 Syndrome

2026-06-23T16:05:00-04:00

PR Newswire
Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)